CORDIS · 810111 · H2020
EpiCrest2Reg From Epigenetics of Cranial Neural Crest Plasticity to Intervertebral Disc Regeneration
Coordinator: FRIEDRICH MIESCHER INSTITUTE FOR BIOMEDICAL RESEARCH FONDATION (CH)
During craniofacial development, Cranial Neural Crest Cells (CNCCs) maintain broad plasticity and patterning competence until they make appropriate cartilage and bone structures in response to local cues. We found that CNCC embryonic plasticity involves a specific epigenetic chromatin signature that maintains genes, including Hox genes, in a transcriptionally silent but poised state, so that they can be readily switched to an active state in response to position-specific environmental signals. Are there CNCC-derived subpopulations in the adult face cartilage with similar broad plasticity prop…
About Horizon 2020 (2014–2020)
Horizon 2020 was the EU's flagship research and innovation programme for 2014–2020, with a budget of around €77 billion. It bundled FP7's strands with the EIT and the Competitiveness and Innovation Programme, introduced a stronger societal-challenge orientation, and pushed the funding logic toward closer-to-market innovation. New calls closed in 2020 but funded projects continued through 2024.
EU contribution: €5.3M awarded to the consortium. The project runs over approximately 7 years from 2019-03-01 to 2026-02-28.
Full record on CORDIS — partners, deliverables, publications, news.
Open on cordis.europa.eu → Grant DOI ↗More from CH
see all →- HBP SGA1 — Human Brain Project Specific Grant Agreement 1720270 · H2020 · €89.0M
- HBP SGA2 — Human Brain Project Specific Grant Agreement 2785907 · H2020 · €88.0M
- ATTRACT2 — Breakthrough Innovation Programme for a Pan-European Detection and Imaging Eco-System – Phase-2101004462 · H2020 · €35.0M
- STEMBANCC — Stem cells for Biological Assays of Novel drugs and prediCtive toxiCology (StemBANCC)115439 · FP7 · €26.0M
- IABC PROGRAMME — iABC Programme115721 · FP7 · €24.3M
- ULTRA-DD — Unrestricted Leveraging of Targets for Research Advancement and Drug Discovery115766 · FP7 · €21.2M
Other H2020 projects
see all →- EUROfusion — Implementation of activities described in the Roadmap to Fusion during Horizon 2020 through a Joint programme of the members of the EUROfusion consortium633053 · DE · €678.8M
- H2020 — COST at a turning point: A unique framework for pan-European ST cooperation as clear demonstration of European values681463 · BE · €178.2M
- HBP SGA3 — Human Brain Project Specific Grant Agreement 3945539 · BE · €150.0M
- COVID-19 VACCINES — PROPOSAL FOR FUNDING RESEARCH DEVELOPMENT AND MANUFACTURING OF VACCINE AGAINST COVID-19101018100 · NO · €100.0M
- UNITE4TB — ACADEMIA AND INDUSTRY UNITED INNOVATION AND TREATMENT FOR TUBERCULOSIS101007873 · NL · €92.5M
- ERA4TB — EUROPEAN REGIMEN ACCELERATOR FOR TUBERCULOSIS853989 · ES · €89.8M
Frequently asked questions
- Who funds this research project?
- This project is funded by the European Union through the Horizon 2020 (2014–2020) programme, under the ERC-SyG funding scheme.
- What is the EU contribution?
- The European Commission contributes €5.3M toward a total project budget of €5.3M.
- Which EU programme funds it?
- The project is funded under Horizon 2020 (2014–2020), call ERC-2018-SyG.
- Who coordinates the project?
- The project is coordinated by FRIEDRICH MIESCHER INSTITUTE FOR BIOMEDICAL RESEARCH FONDATION (CH).
- What is the project timeline?
- The project runs from 2019-03-01 to 2026-02-28 — approximately 7 years.
- Where can I find the full project record?
- The complete record — partners, deliverables, publications and news — is published on CORDIS under project ID 810111.